Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Robert J. Glynn"'
Publikováno v:
Emerging Themes in Epidemiology, Vol 13, Iss 1, Pp 1-10 (2016)
Abstract Background Multivariable confounder adjustment in comparative studies of newly marketed drugs can be limited by small numbers of exposed patients and even fewer outcomes. Disease risk scores (DRSs) developed in historical comparator drug use
Externí odkaz:
https://doaj.org/article/f5389c689b434ced8cc9feec8da3ffec
Autor:
Robert J. Glynn, Cynthia J. Girman, Danica Marinac-Dabic, Alan R. Ellis, Kenneth J. Rothman, Tiansheng Wang, Mark Lunt, Michael Webster-Clark, Kenneth K.C. Man, Mugdha Gokhale, Til Stürmer
Publikováno v:
Webster-Clark, M, Stürmer, T, Wang, T, Man, K, Marinac-Dabic, D, Rothman, K J, Ellis, A R, Gokhale, M, Lunt, M, Girman, C & Glynn, R J 2021, ' Using propensity scores to estimate effects of treatment initiation decisions : State of the science ', Statistics in medicine, vol. 40, no. 7, pp. 1718-1735 . https://doi.org/10.1002/sim.8866
Confounding can cause substantial bias in nonexperimental studies that aim to estimate causal effects. Propensity score methods allow researchers to reduce bias from measured confounding by summarizing the distributions of many measured confounders i
Publikováno v:
Clinical Pharmacology & Therapeutics. 107:735-737
Actionable real-world evidence (RWE) requires accurate estimation of causal treatment effects. Calibration of RWE against randomized controlled trials (RCTs) is sometimes done to demonstrate that RWE can support the same causal conclusion as RCTs. Di
Autor:
Sara K. Tedeschi, Seoyoung C. Kim, Sebastien Haneuse, Houchen Lyu, Elisabetta Patorno, Kazuki Yoshida, Daniel H. Solomon, Robert J. Glynn, Sonia Hernandez-Diaz
Publikováno v:
Pharmacoepidemiology and Drug Safety. 28:934-941
Purpose In observational research, equipoise concerns whether groups being compared are similar enough for valid inference. Empirical equipoise was previously proposed as a tool to assess patient similarity based on propensity scores (PS). We extende
Publikováno v:
Pharmacoepidemiology and Drug Safety. 28:665-670
Purpose Implementing a cohort study in longitudinal healthcare databases requires looking back over some covariate assessment period (CAP) preceding cohort entry to measure confounders. We used simulations to compare fixed-duration versus all-availab
Autor:
Jennifer L. Lund, Michael Webster-Clark, Kenneth J. Rothman, Mark Lunt, Til Stürmer, Richard Wyss, Alan R. Ellis, Robert J. Glynn
Publikováno v:
Am J Epidemiol
To extend previous simulations on the performance of propensity score (PS) weighting and trimming methods to settings without and with unmeasured confounding, Poisson outcomes, and various strengths of treatment prediction (PS c statistic), we simula
Publikováno v:
Pharmacoepidemiology and drug safetyREFERENCES. 29(9)
PURPOSE When investigators have two claims-based definitions for a binary confounder, it is unclear whether to prefer the more sensitive or more specific definition. Our objective was to compare adjusting for the sensitive or specific definition alon
Autor:
Michele Jonsson Funk, Charles Poole, Mitchell M. Conover, Ross J. Simpson, Robert J. Glynn, Til Stürmer, Virginia Pate
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:771-780
PURPOSE Evaluate use of fixed and all-available look-backs to identify eligibility criteria and confounders among Medicare beneficiaries. METHODS We identified outpatient visits (2007-2012) with recently documented (≤180 days) cardiovascular risk a
Autor:
Michael A. Fischer, Shirley V. Wang, Jessica M. Franklin, Krista F. Huybrechts, Sebastian Schneeweiss, Joshua J. Gagne, Robert J. Glynn
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:383-390
Purpose To explore generalized boosted modeling (GBM) as a method for identifying subgroups with greater benefit or harm with dabigatran versus warfarin for treatment of atrial fibrillation. Methods We identified new initiators of warfarin or dabigat
PURPOSE To describe changing roles of predictors of statin initiation before and after incident coronary heart disease, and before and after publication of National Cholesterol Education Program Adult Treatment Panel-III (ATP-III) guidelines in a coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b924f33651c724c9c5636ab9ed67bc
https://europepmc.org/articles/PMC7147936/
https://europepmc.org/articles/PMC7147936/